The investigational anti-PD-1 antibody sintilimab (Tyvyt, Innovent Biologics and Eli Lilly) has confirmed that it improves the efficacy of platinum-primarily primarily based chemotherapy within the…
The investigational anti-PD-1 antibody sintilimab (Tyvyt, Innovent Biologics and Eli Lilly) has confirmed that it improves the efficacy of platinum-primarily primarily based chemotherapy within the…